Dr Hecht on the Investigation of the Novel CAR T-Cell Therapy A2B530 in Solid Tumors
September 25th 2023
J. Randolph (Randy) Hecht, MD, discusses the observational BASECAMP-1 study and the investigation of HLA-A*02 as a target for the novel CAR T-cell therapy A2B530 in the phase 1/2 EVEREST-1 study, which will investigate A2B530 in patients with solid tumors.